Valeant Abandoning its Growth by Acquisition Strategy -Reuters By: Benzinga via Benzinga December 09, 2014 at 05:13 AM EST Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is putting aside its acquisition strategy, according to sources, as reported by ... Read More >> Related Stocks: Actavis Plc Macy's Valeant Pharmaceuticals International, Inc.